anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A self-heating cosmetic composition comprises an oxidant and a reducing agent maintained separately from one another, the usual ingredients of a cosmetic composition being associated with either or both parts of the composition, at least one part of which is aqueous, the oxidant being hydrogen peroxide or urea hydrogen peroxide and the reducing agent being thiourea or a compound of the general formula <FORM:1088301/A5-A6/1> wherein R1 and R2 may each be an alkyl, hydroxyalkyl, alkoxy or alkanoyl group having up to 5 carbon atoms and additionally R1 may be hydrogen and R2 may be phenyl (e.g. 1-phenyl-5-ethyl 2-thiobarbituric acid or 1-methyl-2-thiobarbituric acid or 1-phenyl-2-thiobarbituric acid), the concentrations of the oxidant and reducing agent in their respective parts of the composition being such that, when the parts are mixed together, there is a sensible temperature rise (i.e. at least 25 DEG F. from room temperature within one minute) in the composition.  A catalyst (e.g. an alkali metal or ammonium tungstate or molybdate) for the reaction may be included in the part containing the reducing agent.  The composition may also contain a buffer ingredient (e.g. a polyalkanolamine having up to 9 carbon atoms) in an amount such that the mixed composition has a pH from 5 to 10.  Conventional stabilizers (e.g. phenacetin, stannates and acid phosphates) may be present in the part of the composition containing the peroxides.  A self-foaming composition may be obtained when carbonate or bicarbonate is present and an acid by-product is produced during the exothermic reaction.  The composition may be in a package having two compartments for separate storage of the ingredients and from which they are adapted to be dispensed simultaneously for reaction, one compartment containing the oxidant and the other containing the reducing agent.  The composition preferably includes a liquefied gas propellant under pressure for expelling the ingredients from the compartments.  The composition is preferably a shaving preparation, but may also take the form of a shampoo, hair conditioning rinse, hair bleach, hair dye, hair dye remover or a composition to be applied to the skin.
Two-year oral carcinogenicity studies were conducted in both male and female rats and mice at doses of 5, 15 or 75 mg/kg/day of bicalutamide. A variety of tumor target organ effects were identified and were attributed to the antiandrogenicity of bicalutamide, namely, testicular benign interstitial (Leydig) cell tumors in male rats at all dose levels (the steady-state plasma concentration with the 5 mg/kg/day dose is approximately 2/3 human therapeutic concentrations1) and uterine adenocarcinoma in female rats at 75 mg/kg/day (approximately 1 1/2 times the human therapeutic concentrations1). There is no evidence of Leydig cell hyperplasia in patients; uterine tumors are not relevant to the indicated patient population.

A small increase in the incidence of hepatocellular carcinoma in male mice given 75 mg/kg/day of bicalutamide (approximately 4 times human therapeutic concentrations1) and an increased incidence of benign thyroid follicular cell adenomas in rats given 5 mg/kg/day (approximately 2/3 human therapeutic concentrations1) and above were recorded. These neoplastic changes were progressions of non-neoplastic changes related to hepatic enzyme induction observed in animal toxicity studies. Enzyme induction has not been observed following bicalutamide administration in man. There were no tumorigenic effects suggestive of genotoxic carcinogenesis.

A comprehensive battery of both in vitro and in vivo genotoxicity tests (yeast gene conversion, Ames, E. coli, CHO/HGPRT, human lymphocyte cytogenetic, mouse micronucleus, and rat bone marrow cytogenetic tests) has demonstrated that Bicalutamide Tablets, USP does not have genotoxic activity.

Administration of Bicalutamide Tablets, USP may lead to inhibition of spermatogenesis. The long-term effects of Bicalutamide Tablets, USP on male fertility have not been studied.

In male rats dosed at 250 mg/kg/day (approximately 2 times human therapeutic concentrations1), the precoital interval and time to successful mating were increased in the first pairing but no effects on fertility following successful mating were seen. These effects were reversed by 7 weeks after the end of an 11-week period of dosing.

No effects on female rats dosed at 10, 50 and 250 mg/kg/day (approximately 2/3, 1 and 2 times human therapeutic concentrations, respectively1) or their female offspring were observed. Administration of bicalutamide to pregnant females resulted in feminization of the male offspring leading to hypospadias at all dose levels. Affected male offspring were also impotent.

* * *

1
    Based on a maximum dose of 50 mg/day of bicalutamide for an average 70 kg patient.
PURPOSE: The present study describes a new presurgical soft tissue technique in oral/maxillary bone reconstructive surgery for reducing the risk of soft tissue dehiscence and its related complications.
MATERIALS AND METHODS: Ten consecutive patients with Cawood and Howell type V atrophy were scheduled for CAD/CAM titanium mesh bone reconstructive surgery after applying the vascular delay technique 21 days before regenerative surgery. The surgical and healing complications were clinically assessed at nine time points, ranging from the time of bone regenerative surgery to 9 months after surgery. Surgical complications included flap damage and neurologic and vascular complications. Healing complications were subdivided into four classes. These classes comprised Class I: small membrane exposure (≤ 3 mm) without purulent exudate; Class II: large membrane exposure (> 3 mm) without purulent exudate; Class III: membrane exposure with purulent exudate; and Class IV: abscess formation without membrane.
RESULTS: The study sample included seven men and three women (mean age: 48.2 ± 3.5 years) with seven mandibular cases and three maxillary cases. The defect length ranged from three to six teeth, with a mean mesiodistal distance of 29.9 ± 8.5 mm and a mean volume augmentation of 2.03 ± 0.9 cm3. There were no surgical complications. One patient presented a Class I healing complication that did not affect the regeneration outcome.
CONCLUSIONS: The vascular delay technique appears to reduce the risk of soft tissue dehiscence and exposure in bone regenerative surgery, though randomized studies involving larger samples and longer follow-up periods are needed in order to draw firm conclusions.
Participants will not receive any intervention as a part of this study. SGLT2i includes canagliflozin, dapagliflozin, empagliflozin as prescribed in clinical practice. Participants will be evaluated in 2 sub-cohorts (with or without high CV risk) and overall.
Targeted modulation of a dynamic interplay between transcription factor nuclear factor erythroid 2-related factor 2 (NRF2) and its negative regulator, Kelch-like ECH-associated protein 1 (KEAP1), is of paramount importance in maintaining redox, metabolic, and protein homeostasis and regulating inflammation responses. Indeed, inducible NRF2 activation promotes cytoprotective mechanisms against many immune, neurodegenerative, and metabolic disorders with oxidative stress and inflammation as underlying pathological features. In this ARS Forum, five state-of-the-art reviews and two original research communications report on canonical and newly discovered molecular mechanisms by which the NRF2-KEAP1 axis controls fundamental cell life or death decisions and exerts biological functions under environmental and endogenous stress conditions. Although the use of NRF2 activators represents a promising pharmacological strategy to regain and maintain homeostasis, challenges regarding their double-edged character, target specificity, pharmacodynamic properties, efficacy, and safety must be critically considered. More translational studies are warranted before NRF2 agonists (inducers or enhancers) become an integral part of our therapeutic armamentarium. Antioxid. Redox Signal. 40, 632-635.
Smoking is injurious to health as cigarette contains harmful substances that cause different life threatening diseases, like bronchitis, asthma, chronic obstructive pulmonary disease (COPD), cardiovascular diseases etc. During normal breathing, oxygen is supplied to the body through blood circulation. But, in smokers, carbon monoxide (CO) is supplied to body instead of oxygen, resulting in respiratory issues, like breathlessness and coughing, in acute stages . Smoking decreases lung capacity, as it contains acidic substances which start damaging the lining of the bronchi and bronchioles due to which they become inflamed and infected, resulting into coughing, shortness of breath and chest pain that leads towards chronic bronchitis. This study will contribute our young smokers as they are adherent to smoking and its difficult for them to quit smoking. as their physical activity is limited, individuals under stress condition and with pulmonary complications so impact of this research is that along with helping smokers to quit smoking also applying alternative strategies to minimize complication and improve quality of life. and these alternative strategies include such activities that performed easily at home and do not require much effort or no need to go to gym or any other place to perform these exercises.
DENV infections can cause self-limited but incapacitating acute illness lasting four to seven days. The illness is characterized by fever, headache, severe pain in muscles, joints, pain behind the eyes, and a rash. DENV infection can be complicated by the development of hemorrhagic fever (DHF) or shock syndrome (DSS), which is manifested by plasma leakage and a bleeding diathesis or frank hemorrhage. DHF is fatal in at least 0.5% of pediatric cases but rarely in adults. People, particularly children, living in hyper-endemic areas who have antibodies from an earlier dengue infection with one serotype are at increased risk for DHF if subsequently infected by another dengue virus serotype.

Currently, no specific anti-viral therapy exists. Therapy is largely supportive. Mosquito control has failed to prevent dengue transmission; therefore, prevention of dengue through vaccination is an important objective of the World Health Organization (WHO) and many national governments, including the United States.
Moderate traumatic brain injury (mTBI) involves a series of complex pathophysiological processes in not only the area in direct contact with mechanical violence but also in other brain regions far from the injury site, which may be important factors influencing subsequent neurological dysfunction or death. The medulla oblongata (MO) is a key area for the maintenance of basic respiratory and circulatory functions, whereas the pathophysiological processes after mTBI have rarely drawn the attention of researchers. In this study, we established a closed-head cortical contusion injury model, identified 6 different time points that covered the acute, subacute, and chronic phases, and then used nontargeted metabolomics to identify and analyze the changes in differential metabolites (DMs) and metabolic pathways in the MO region. Our results showed that the metabolic profile of the MO region underwent specific changes over time: harmaline, riboflavin, and dephospho-coenzyme A were identified as the key DMs and play important roles in reducing inflammation, enhancing antioxidation, and maintaining homeostasis. Choline and glycerophospholipid metabolism was identified as the key pathway related to the changes in MO metabolism at different phases. In addition, we confirmed increases in the levels of inflammatory factors and the activation of astrocytes and microglia by Western blot and immunofluorescence staining, and these findings were consistent with the nontargeted metabolomic results. These findings suggest that neuroinflammation plays a central role in MO neuropathology after mTBI and provide new insights into the complex pathophysiologic mechanisms involved after mTBI.
Cobamamide or mecobalamin, used for treating pernicious anemia, are stabilized in solid prepns. against light by adding dyes such a New Coccine. Thus, mecobalamine 0.1g, New Coccine 0.1g, and mannitol 98g were mixed and the mixt. was then kneaded with 20 mL of 10% EtOH  soln. of hydroxypropyl cellulose. This was then granulated and dried for 10 hrs. The granular product was then dressed to give a product in the grain range of 1410-500μ.
BACKGROUND: Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a heterogeneous but treatable immune-mediated neuropathy. Ofatumumab (OFA) is a fully human anti-CD20 monoclonal antibody that has shown promising efficacy in central demyelinating diseases, such as multiple sclerosis (MS). However, there is a lack of studies on the usage of OFA in peripheral demyelinating diseases, particularly CIDP. A case of relapsed and refractory CIDP with an ineffective response to conventional immunotherapy and intolerance to rituximab (RTX) but a positive response to subcutaneous injections of OFA is presented.
CASE PRESENTATION: The patient, a 46-year-old man diagnosed with CIDP, received high-dose intravenous methylprednisolone, intravenous immunoglobulin (IVIG), and plasma exchange(PE) during the acute phase of the disease, and long-term oral administration of prednisone, azathioprine (AZA), and mycophenolate mofetil (MMF) during the remission phase. However, the patient suffered six relapses over a five-year period, and because of these, along with an ineffective response to conventional immunotherapy, and intolerance to RTX, subcutaneous injections of OFA were selected as a prophylactic treatment against relapses. After a total of six injections of OFA, CD19+B cells were substantially depleted. The patient has been followed for more than 23 months without relapse.
CONCLUSIONS: This case demonstrates the effectiveness and good tolerability of OFA in the treatment of relapsed and refractory CIDP. Further studies are needed to investigate the efficacy and safety of OFA in patients with relapsed and refractory CIDP, especially in those who have shown an ineffective response to conventional immunotherapy and are intolerant to RTX.
Depending on body weight, patients will be divided into two groups. Women with a body weight \<70 kg will be taking a daily dose of 800 mg ibuprofen orally. Women ≥ 70 kg will take a dose of 1200 mg ibuprofen orally. Before and after 3 weeks of treatment, all subjects will have a full hormonal, biochemical and clinical profile.
This is a multi-staged, mixed methods study that leverages a naturally occurring policy experiment in southern Ohio. In aim 1, we will examine the collaborative strategies associated with implementation and service outcomes, given the context with 17 counties engaged in the Ohio START pilot project. We will use a convergent mixed methods design, and integrate our qualitative and quantitative data using qualitative comparative analysis. For aim 2, we will specify the collaborative strategies and develop a decision support guide using the VA's model of implementation strategy development (diagnose barriers, and convene an expert panel to design strategies). For aim 3, we assess the feasibility, acceptability, and appropriateness of the decision support guide using a sequential mixed methods design. In the first quantitative phase, we will conduct a randomized vignette experiment with agency directors in the 71 Ohio counties that are not involved in the Ohio START pilot project to compare the decision support guide with general implementation support. Our second qualitative phase (which is dominant), will examine feasibility more in-depth by piloting the guide and conducting descriptive case studies with up to three new counties.
The subject invention relates to a skin cream that can be used to moisturize and rejuvenate skin that has been damaged by exposure to sunlight or which has simply been affected over the years by intrinsic aging. It can also be used to slow the rate of photo-induced aging to maintain beautiful skin tone and texture over the years. It inhibits the formation of wrinkles and in some cases reduces the depth of existing wrinkles or eliminates them entirely. In some cases, the skin cream of this invention also lightens age spots and other types of blemishes associated with aging. This invention is based upon the discovery that alkyl lactates, such as ethyl lactate, can be used to improve the penetration of active ingredients in skin care formulations deep into lower layers of the skin tissue. For instance, ethyl lactate can be included in aqueous based skin creams, such as oil in water emulsions, to deliver active ingredients deep into the skin structure. Ethyl lactate is particularly desirable for utilization in conjunction with ascorbic acid (Vitamin C) containing skin cream formulations. This is beneficial because the overall effectiveness of skin creams that utilize ascorbic acid as an active ingredient is contingent upon delivery of the ascorbic acid through the outer layers of the stratum corneum and viable epidermis and into the dermis layer of the skin structure. The present invention more specifically discloses a topical formulation comprising about 1 weight percent to about 20 weight percent ascorbic acid, about 1 weight percent to about 10 weight percent of an amino acid selected from the group consisting of phenylalanine and tyrosine, about 0.5 weight percent to about 5 weight percent of a non-toxic zinc salt, about 0.01 weight percent to about 20 weight percent of an alkyl lactate, wherein the alkyl group in the alkyl lactate contains from 2 to about 12 carbon atoms, and a pharmaceutically acceptable carrier.
The present invention relates to an orally administrable galenic form allowing improved absorption by the transmembrane or paracellular route in the gastrointestinal tract of active ingredients which are hydrophilic or ionizable in physiol. media, comprising at least one such active ingredient, an absorption-promoting agent having an HLB>8, the the absorption-promoting agent consisting of one or more lipid substances chosen from: polysorbates; polyoxyethylene ethers; esters of polyoxyethylene and fatty acids; fatty acids; fatty alcs.; bile acids and their salts with pharmaceutically acceptable cations; esters of C1-C6 alkanol with fatty acids; esters of polyol with fatty acids, the polyol comprising from 2 to 6 hydroxyl functional groups; and polyglycolyzed glycerides; in combination with one or more pharmaceutically acceptable excipients, the pharmaceutical forms comprising captopril being excluded. A controlled-release tablet contained (1) cores contg. calcium acamprosate 50, Gelucire 44/14 10, Compritol 10, microcryst. cellulose 19, Povidone 10, and Mg stearate 1% and (2) a film-coating compn. contg. HPMC 64, PEG-4000 15, and talc 21%.
PURPOSE: A pharmaceutical composition containing Prunus yedoensis bark extract or prunetin is provided to enable maximal relaxation. CONSTITUTION: A pharmaceutical composition for preventing or treating vascular diseases contains Prunus yedoensis bark extract as an active ingredient. The extract is prepared using water, alcohol of C1-C4, or a mixture solvent thereof. The ethanol is methanol or ethanol. The pharmaceutical composition contains prunetin compounds of chemical formula 1 or pharmaceutically acceptable salt thereof as an active ingredient. The prunetin compound is isolated from Prunus yedoensis bark extract.
Zonegran / Placebo Zonisamide (Zonegran ®) and its placebo appear under the shape of virgin capsules of size 1. Each drug will be dispensed successively in a box containing blister packs of 14 capsules. For every period (A and B), box will contain 26 blister packs. A phase of progressive increase of doses by stages of 50 mg / week is planned before reaching the fixed dose of 300 in the daytime during 4 weeks. Then, a progressive diminution over two weeks is planned before the stop.
Stage 1 participants will receive IONIS-FB-LRx randomized to 1 of 3 dose levels, administered subcutaneously every 4 weeks, completing the treatment period at Week 45. Stage 2 will expand 2 of the dosing cohorts in a new randomized group of participants based on the Stage 1 interim analysis. Participants will be randomized to 1 of 2 of the expanded cohorts, administered subcutaneously every 4 weeks, completing the treatment period at Week 45.
FIELD: cosmetic compositions.SUBSTANCE: group of inventions relates to the field of cosmetic compositions. Composition for reducing, preventing or eliminating the presence or signs of a skin condition disorder, which is selected from signs of skin aging, acne or rosacea, contains from 0.001% by wt. to 5% by wt. of retinol and from 0.1% by wt. to 5% by wt. of potato dextrinadodecenylsuccinate sodium, wherein the specified composition is an “oil-in-water” emulsion. Another option of the composition and a method for skin treatment are also disclosed.EFFECT: group of inventions provides improved retinoid activity to eliminate signs of skin aging, acne or rosacea.3 cl, 4 tbl, 2 ex
All patients underwent preoperative investigations and imaging study (CT Urogram/Intravenous Pyelography) done prior to the operation as per standard operation preparation. Intraoperatively fluoroscopic imaging was done for the patients and the images were synchronized to the software. Robotic arm was placed on the site of surgery as for prone PCNL and diaphragm of the arm was centred over the site of desire calyx of entry. A needle was engaged into the centre of the diaphragm and using the software the need was aligned in the line of puncture automatically based on the fluoroscopic images. After the alignment was done the needle was advanced manually by the surgeon until the entry was confirmed by efflux of urine from the puncture needle. After the entry was confirmed a standard PCNL using 24 F or 30 F Balloon dilator was performed and stone cleared using Cyberwand/ Shockpulse etc. All the intraoperative and perioperative parameters as mentioned in the data collection form was measured. Results was analysed with the main focus on time of obtaining the puncture, accuracy of puncture, radiation exposure time till calyceal entry which was confirmed by free flow of urine and for any complications.

Patients aged between 21 to 75 years old who were diagnosed with kidney stone diseas and planned for prone PCNL with indication for surgery as per standard of care were recruited. They understood the purpose of testing and offered their voluntary and informed consent.

The robotic device i.e. ANT lesses the learning curve of percutaneous access as it reduces the need for surgeon's visualization of the calyceal system and the needle alignment. It also improved efficiency as there is less dependence on human skills during the procedure. As a whole, the FIM trial was a success. The performance of the ANT system during the trial was satisfactory. The robot alignment time is less than 30 seconds. Total puncture time was around 6 minutes and no AEs were reported.
When Alfentanil HCl Injection is used with CNS depressants, hypotension can occur. If it occurs, consider the possibility of hypovolemia and manage with appropriate parenteral fluid therapy. When operative conditions permit, consider repositioning the patient to improve venous return to the heart. Exercise care in moving and repositioning of patients because of the possibility of orthostatic hypotension. If volume expansion with fluids plus other countermeasures do not correct hypotension, consider administration of pressor agents other than epinephrine. Epinephrine may paradoxically decrease blood pressure in patients treated with a neuroleptic that blocks alpha adrenergic activity [see Drug Interactions (7)].
Vortioxetine 10 mg, capsules, orally, once, daily (QD) up to 8 weeks. Participants who achieved response (defined as a ≥50% reduction in Montgomery Asberg Depression Rating Scale (MADRS) total score from Baseline) continued to receive vortioxetine 10 mg, capsules, orally, QD for up to Week 16 (stabilization period) in the Open-label Period.